debt_leverage_profile
Micro-cap biotech; net debt near zero with ~$5–15M cash runway; 20% rate rise immaterial but accelerates cash burn timeline
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal direct debt sensitivity; higher rates compress biotech valuations via DCF discount rate expansion, increasing equity dilution risk
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredient (API) synthesis in China/India; specialized radioisotope or psychedelic precursor sourcing from regulated jurisdictions (Canada, Netherlands)
Inferred
Agent_Inference
international_expansion_readiness
Limited international revenue; CAD/USD exposure from Canadian operations; minimal FX hedging typical for micro-cap; sovereign devaluation risk low but unmanaged
Inferred
Agent_Inference
geographic_footprint
Primarily Canada-listed (CSE/TSX-V) with US OTC presence; operations in Canada; nascent EU/Caribbean regulatory filings; FX exposure largely CAD-USD
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single licensed psychedelic compound suppliers and GMP contract manufacturers; substitution difficult given regulatory approval linkages
Inferred
Agent_Inference
business_model_type_primary
Pre-revenue clinical-stage biopharma; no material cloud infrastructure dependency; data hosted via CRO platforms—30-day termination would disrupt trial data access
Inferred
Agent_Inference
business_model_type_secondary
Hybrid CRO-dependent model; secondary reliance on electronic data capture (EDC) vendors like Medidata or Veeva for clinical trial management
Inferred
Agent_Inference
switching_cost_profile
High API coupling risk to proprietary CRO/EDC systems; switching mid-trial violates regulatory continuity; estimated 6–18 month and $500K+ switching cost
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is pharmaceutical IP licensing/development, not investment contract; no token or profit-sharing structure identified
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure from EU clinical trial participant data; CCPA limited; compliance depends on CRO data handling agreements; audit trail risk present
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible; pre-revenue micro-cap with no market share; no horizontal or vertical integration concerns at current scale
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~0% recurring revenue currently; 100% transactional/grant-based or milestone-contingent; pre-commercial stage with no subscription or retainer income
Inferred
Agent_Inference
monetization_vector
Primary monetization via future IP licensing, milestone payments from pharma partners, or eventual drug commercialization; no current product revenue
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture yet; future pricing will follow specialty pharma model (~$10K–$50K/course for psychedelic-assisted therapy) subject to payer negotiation
Inferred
Agent_Inference
pricing_power_rating
Potentially high if first-mover in approved indication; pricing power contingent on FDA/Health Canada approval and lack of therapeutic substitutes
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 70–85% at commercialization, consistent with specialty pharma; currently negative gross margin in R&D phase
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage risk at current stage; post-commercialization, off-label compounding pharmacies could undercut branded pricing
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth will be sublinear to headcount post-approval; commercialization requires salesforce build but manufacturing is outsourced, limiting linear scaling
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is low post-approval given outsourced manufacturing; primary scale cost is regulatory affairs, medical affairs, and distribution partnerships
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company does not operate a franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC dominated by medical education and physician detailing; estimated $2,000–$8,000 per prescribing clinician in specialty pharma context
Inferred
Agent_Inference
network_effect_present
No network effects present; pharmaceutical value is IP and clinical evidence-based, not user-network dependent
Inferred
Agent_Inference
asset_efficiency_ratio
AI displaces limited functions (drug discovery screening, trial design); core value in regulatory IP and clinical data, not headcount-intensive processes
Inferred
Agent_Inference
recession_resistance_tier
Moderate recession resistance; mental health treatment demand is inelastic but reimbursement and discretionary out-of-pocket spend compress in downturns
Inferred
Agent_Inference
customer_segment_primary
Primary future customer: psychiatrists, addiction medicine specialists, and licensed psychedelic-assisted therapy clinics in Canada and US
Inferred
Agent_Inference
customer_segment_secondary
Secondary: institutional pharma partners seeking licensing deals; government health agencies (VA, provincial health authorities) for pilot programs
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated to clinical trials and regulatory submissions, not legacy infrastructure; no legacy reallocation needed; pure forward-state R&D deployment
Inferred
Agent_Inference
sec_cik
0001771885
High
SEC-EDGAR
ticker
QNTM
High
SEC-EDGAR